Determination of non-α1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: Analytical performance and diagnostic accuracy

Clinical Chemistry

Volumn 49, Issue 6, 2003, Pages 887-894

  Wesseling, Sebastian ^a   Stephan, Carsten ^a   Semjonow, Axel ^b   Lein, Michael ^b   Brux, Brigitte ^a   Sinha, Pranav ^a   Loening, Stefan A ^a   Jung, Klaus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; CHYMOTRYPSIN A; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALYTIC METHOD; ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRECIPITATION; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BINDING; PROTEIN BLOOD LEVEL; RESIDUE ANALYSIS; ROC CURVE; SAMPLING; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; AUTOANALYSIS; BLOOD; CHEMOLUMINESCENCE; CLINICAL TRIAL; IMMUNOASSAY; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PROSTATE TUMOR; RETROSPECTIVE STUDY;

AGED; ALPHA 1-ANTICHYMOTRYPSIN; AUTOANALYSIS; CHEMILUMINESCENT MEASUREMENTS; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEIN BINDING; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 0038697614     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/49.6.887     Document Type: Article

References (31)

1. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324: 1156-61.
2. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, et al. Prostate-specific antigen in serum occurs predominantly in complex with α 1-antichymotrypsin. Clin Chem 1991;37:1618-25.
3. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51: 222-6.
4. 1-antichymotrypsin as an indicator of prostate Cancer. J Urol 1993;150:100-5.
5. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery - what we have learned and where we are going [Review]. J Urol 1999;162:293-306.
6. 1-protease inhibitor in serum. Clin Chem 1999;45:814-21.
7. Zhang WM, Finne P, Leinonen J, Salo J, Stenman UH. Determination of prostate-specific antigen complexed to α(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer. Urology 2000;56:267-72.
8. Stephan C, Jung K, Lein M, Sinha P, Schnorr D, Loening SA. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol Biomarkers Prev 2000;9:1133-47.
9. Zhou AM, Tewari PC, Bluestein BI, Caldwell GW, Larsen FL. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays. Clin Chem 1993;39:2483-91.
10. Strobel SA, Sokoloff RL, Wolfert RL, Rittenhouse HG. Multiple forms of prostate-specific antigen in serum measured differently in equimolar- and skewed-response assays. Clin Chem 1995;41: 125-7.
11. Cheli CD, Marcus M, Levine J, Zhou Z, Anderson PH, Bankson DD, et al. Variation in the quantitation of prostate-specific antigen in reference material: differences in commercial immunoassays. Clin Chem 1998;44:1551-3.
12. Semjonow A, Oberpenning F, Brandt B, Zechel C, Brandau W, Hertle L. Impact of free-prostate specific antigen on discordant measurement results of assays for total prostate-specific antigen. Urology 48(Suppl 6A):10-5, 1996.
13. Wu JT. Assay for prostate specific antigen (PSA): problems and possible solutions. J Clin Lab Anal 1994;8:51-62.
14. Brawer MK. Clinical usefulness of assays for complexed prostate-specific antigen [Review]. Urol Clin North Am 2002;29:193-203, xi.
15. Stephan C, Jung K, Schnorr D, Lein M, Sinha P, Loening SA. RE: A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer [Letter]. J Urol 2002;167:259-61.
16. Okihara K, Cheli CD, Partin AW, Fritche HA, Chan DW, Sokoll LJ, et al. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol 2002;167:2017-23.
17. Stenman UH. Immunoassay standardization: is it possible, who is responsible, who is capable [Editorial]? Clin Chem 2001;47:815-20.
18. Sokoll LJ, Partin AW, Bruzek DJ, Mohr P, Chan DW. Non-α1-antichymotrypsin complexed PSA: a new approach to spare unnecessary biopsies [Abstract]. J Urol 2000;163:237.
19. Bach M, Jung K, Ivankovic B, Mack M. LIAISON fPSA: development of an alternative method for the determination of free PSA on the fully automated chemiluminescence LIAISON immunoassay analyser [Abstract]. Clin Chem 2000;46(Suppl 6):A160.
20. Molina R, Bonfrer J, Banfi G, Bugugnani MJ, Cornu F, Hannemann-Pohl K, et al. External evaluation of LIAISON tumour marker assays on the fully automated chemiluminescent LIAISON immunoassay analyser. Clin Lab 2000;46:169-79.
21. Meyer A, Jung K, Lein M, Rudolph B, Schnorr D, Loening SA. Factors influencing the ratio of free to total prostate-specific antigen in serum. Int J Cancer 1997;74:630-6.
22. Stephan C, Jung K, Brux B, Lein M, Sinha p, Schnorr D, et al. ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: proof of new complex forming of PSA after release into circulation. Urology 2000;55:560-3.
23. Konig B, Ivankovic B, Schleff R, Mack M. Liaison free PSA - an automated chemiluminescent immunoassay for the determination of free prostate specific antigen (fPSA). Anticancer Res 1999;19: 2763-5.
24. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry. Part I. J Clin Chem Clin Biochem 1983;21:709-20.
25. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999;8:135-60.
26. Kairisto V, Poola A. Software for illustrative presentation of basic clinical characteristics of laboratory tests - GraphROC for Windows. Scand J Clin Lab Invest 1995;55(Suppl 222):43-60.
27. Nagasaki H, Watanabe M, Komatsu N, Kaneko T, Dube JY, Kajita T, et al. Epitope analysis of a prostate-specific antigen (PSA) C-terminal-specific monoclonal antibody and new aspects for the discrepancy between equimolar and skewed PSA assays. Clin Chem 1999;45:486-96.
28. Semjonow A, Oberpenning F, Weining C, Schon M, Brandt B, De Angelis G, et al. Do modifications of nonequimolar assays for total prostate-specific antigen improve detection of prostate cancer? Clin Chem 2001;47:1472-5.
29. Catalona WJ. Clinical utility of measurements of free and total prostate-specific antigen (PSA): a review. Prostate 1996;29(Suppl S7):64-9.
30. van lersel MP, Witjes WPJ, Thomas CMG, Segers MFG, Oosterhof GON, Debruyne FMJ. Review on the simultaneous determination of total prostate-specific antigen and free prostate-specific antigen. Prostate 1996;29(Suppl S7):48-57.
31. Lein M, Stephan C, Jung K, Schnorr D, Loening S. Relation of free PSA/total PSA in serum for differentiating between patients with prostatic cancer and benign hyperplasia of the prostate - which cutoff should be used? Cancer Invest 1998;16:45-9.